Back to Search
Start Over
Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
- Source :
-
Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Jan 19; Vol. 27 (2), pp. 155-161. - Publication Year :
- 2021
-
Abstract
- Background: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).<br />Methods: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.<br />Results: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.<br />Conclusions: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD.<br /> (© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
COVID-19 epidemiology
COVID-19 virology
Colitis, Ulcerative drug therapy
Colitis, Ulcerative virology
Crohn Disease drug therapy
Crohn Disease virology
Female
Humans
Inflammatory Bowel Diseases virology
Male
Middle Aged
Odds Ratio
Regression Analysis
Risk Factors
Young Adult
Biological Products adverse effects
COVID-19 chemically induced
Immunosuppressive Agents adverse effects
Inflammatory Bowel Diseases drug therapy
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 1536-4844
- Volume :
- 27
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Inflammatory bowel diseases
- Publication Type :
- Academic Journal
- Accession number :
- 33089863
- Full Text :
- https://doi.org/10.1093/ibd/izaa278